IMRN
Immuron Ltd ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.11M
P/E Ratio
—
EPS
$-0.50
Beta
0.36
52W High
$2.39
52W Low
$0.68
50-Day MA
$0.80
200-Day MA
$1.44
Dividend Yield
—
Profit Margin
-62.10%
Forward P/E
—
PEG Ratio
0.00
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
Fundamentals
| Revenue (TTM) | $7.48M |
| Gross Profit (TTM) | $4.76M |
| EBITDA | $-4.74M |
| Operating Margin | -47.20% |
| Return on Equity | -39.70% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $1.16 |
| Book Value | $1.11 |
| Price-to-Book | 0.72 |
| Price-to-Sales (TTM) | 1.08 |
| EV/Revenue | 0.854 |
| EV/EBITDA | 0.77 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 4.80% |
| Shares Outstanding | $8.17M |
| Float | $322.66M |
| % Insiders | 0.00% |
| % Institutions | 2.01% |
Analyst Ratings
Consensus ($3.95 target)
1
Strong BuyData last updated: 4/8/2026